MX2015016978A - Proteinas de union a antigeno neutralizantes de citomegalovirus. - Google Patents

Proteinas de union a antigeno neutralizantes de citomegalovirus.

Info

Publication number
MX2015016978A
MX2015016978A MX2015016978A MX2015016978A MX2015016978A MX 2015016978 A MX2015016978 A MX 2015016978A MX 2015016978 A MX2015016978 A MX 2015016978A MX 2015016978 A MX2015016978 A MX 2015016978A MX 2015016978 A MX2015016978 A MX 2015016978A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding proteins
cmv
neutralizing antigen
cmv neutralizing
Prior art date
Application number
MX2015016978A
Other languages
English (en)
Inventor
Zhiqiang An
Tong-Ming Fu
Dai Wang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2015016978A publication Critical patent/MX2015016978A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089Cytomegalovirus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se dirige a proteínas de unión a antígeno incluyendo, pero no limitadas a, anticuerpos monoclonales y fragmentos de unión a antígeno de los mismos, que se unen específicamente a y preferiblemente neutralizan citomegalovirus (CMV) humano; también comprendidos por la invención son las proteínas de unión a antígeno que han sido humanizadas; las proteínas de unión a antígeno de la invención son útiles como un agente terapéutico para tratar y/o prevenir infecciones de CMV en un paciente en necesidad de las mismas.
MX2015016978A 2013-06-10 2014-06-09 Proteinas de union a antigeno neutralizantes de citomegalovirus. MX2015016978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361833184P 2013-06-10 2013-06-10
PCT/US2014/041504 WO2014200898A2 (en) 2013-06-10 2014-06-09 Cmv neutralizing antigen binding proteins

Publications (1)

Publication Number Publication Date
MX2015016978A true MX2015016978A (es) 2016-04-25

Family

ID=52022906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016978A MX2015016978A (es) 2013-06-10 2014-06-09 Proteinas de union a antigeno neutralizantes de citomegalovirus.

Country Status (11)

Country Link
US (1) US9868777B2 (es)
EP (1) EP3008087A4 (es)
JP (1) JP2016521711A (es)
KR (1) KR20160018527A (es)
CN (1) CN105579469A (es)
AU (1) AU2014278481A1 (es)
BR (1) BR112015030892A2 (es)
CA (1) CA2912913A1 (es)
MX (1) MX2015016978A (es)
RU (1) RU2015155601A (es)
WO (1) WO2014200898A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102129107B1 (ko) 2015-03-06 2020-07-02 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 항-lilrb 항체 및 암의 검출 및 치료를 위한 이의 용도
WO2017004151A1 (en) * 2015-06-29 2017-01-05 Regents Of The University Of Minnesota Anti-apobec3 antibodies and methods of making and using
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
IL261666B2 (en) 2016-03-31 2024-09-01 Ngm Biopharmaceuticals Inc Related proteins and methods of using them
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
EP3455251A4 (en) * 2016-05-09 2020-04-22 Icahn School of Medicine at Mount Sinai WIDE NEUTRALIZING HUMAN ANTI-CYTOMEGALOVIRUS ANTIBODIES AND METHODS OF USE
JP2018203632A (ja) * 2017-05-30 2018-12-27 公益財団法人ヒューマンサイエンス振興財団 モノクローナル抗体及び測定キット
CA3067835A1 (en) * 2017-06-22 2018-12-27 Apexigen, Inc. Anti-vista antibodies and methods of use
CN111032689B (zh) 2017-08-24 2024-02-27 凡恩世制药(北京)有限公司 抗爱帕琳肽抗体及其用途
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
US20220056124A1 (en) * 2018-09-05 2022-02-24 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against endotrophin and the use thereof
US10666510B2 (en) 2018-10-30 2020-05-26 Bank Of America Corporation Conserving computing resources during network parallel processing
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CN118580343A (zh) * 2022-10-21 2024-09-03 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361779B1 (en) * 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
US20100034822A1 (en) * 2005-03-30 2010-02-11 Vega Masignani Haemophilus Influenzae Type B
WO2007094423A1 (ja) * 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EA201270662A1 (ru) * 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
JO3274B1 (ar) * 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
WO2011125015A2 (en) 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
EA201390467A1 (ru) 2010-09-29 2013-11-29 Дженентек, Инк. Композиции антител и способы применения
AU2012255143A1 (en) * 2011-05-19 2014-02-20 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
US20130039974A1 (en) * 2011-08-10 2013-02-14 Donald W. Kufe Anti-muc1 antibodies for cancer diagnostics
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製cmv

Also Published As

Publication number Publication date
JP2016521711A (ja) 2016-07-25
AU2014278481A1 (en) 2015-12-03
WO2014200898A3 (en) 2015-04-09
US9868777B2 (en) 2018-01-16
CA2912913A1 (en) 2014-12-18
BR112015030892A2 (pt) 2017-08-29
EP3008087A4 (en) 2017-03-01
CN105579469A (zh) 2016-05-11
US20160130327A1 (en) 2016-05-12
WO2014200898A2 (en) 2014-12-18
EP3008087A2 (en) 2016-04-20
RU2015155601A (ru) 2017-07-14
KR20160018527A (ko) 2016-02-17

Similar Documents

Publication Publication Date Title
MX2015016978A (es) Proteinas de union a antigeno neutralizantes de citomegalovirus.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MD4716C1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
WO2013188870A3 (en) IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
MY184189A (en) Methods of treating nail and scalp psoriasis
MX2020008122A (es) Anticuerpos anti-pd-1.
EA201990895A1 (ru) Антитела к о1 и варианты их применения
PH12015501360A1 (en) Bmp-6 antibodies
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
PH12015501632A1 (en) Humanized anti-hmgbi antibody or antigen-binding fragment thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2017011480A (es) Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo.
MA40526A (fr) Protéines de fixation antigénique fixant le cxcr3
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
WO2014143739A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
WO2014144616A3 (en) Anti-alpha v beta 5 antibodies and uses thereof
WO2012112842A3 (en) Compositions and methods for treating poliovirus